Regadenoson and Adenosine

NCT01809743 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Regadenoson central -central
DRUG: Regadenoson peripheral - peripheral
DRUG: Regadenoson central - peripheral
DRUG: Regadenoson peripheral - central
DRUG: Adenosine

Sponsor

Lokien van Nunen